source
- Eli Lilly removes Gaucher disease gene therapy trial from pipeline, citing unmet internal criteriaEli Lilly has announced the removal of a phase 1/2 study testing its GBA1 gene therapy for Gaucher disease type 1. The program was part of the assets acquired when the company bought Prevail Therap…
- AL Sydbank discloses share transactions by managers and related persons under MARAL Sydbank issued a company announcement (No 41/2026) on 5 August 2026, informing the market of share transactions carried out by its managers and persons closely associated with them. The disclos…